La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Abbott Laboratories Gestion

Gestion contrôle des critères 3/4

Le PDG Abbott Laboratories' est Robert Ford, nommé en Oct2018, a un mandat de 5.83 ans. La rémunération annuelle totale est $ 23.27M, composée du salaire de 6.4% et des bonus 93.6%, y compris les actions et options de la société. détient directement 0.024% des actions de la société, d'une valeur de $ 46.71M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.6 ans et 5.5 ans.

Informations clés

Robert Ford

Directeur général

US$23.3m

Rémunération totale

Pourcentage du salaire du PDG	6.4%
Durée du mandat du directeur général	5.9yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	5.6yrs

Mises à jour récentes de la gestion

Recent updates

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Sep 27

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Sep 11

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Aug 16

Abbott Laboratories: Driving Value By Scaling Innovations

Aug 13

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Aug 05

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Jul 13

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Jul 01

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Jun 18

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Dec 28

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Dec 27

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Dec 03

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Nov 29

Analyse de la rémunération des PDG

Comment la rémunération de Robert Ford a-t-elle évolué par rapport aux bénéfices de Abbott Laboratories?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Rémunération vs marché: La rémunération totale de Robert ($USD 23.27M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).

Rémunération et revenus: La rémunération de Robert a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Robert Ford (50 yo)

5.9yrs

Titularisation

US$23,268,171

Compensation

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Robert Ford	Chairman of the Board	5.9yrs	US$23.27m	0.024% $ 46.9m
Philip Boudreau	CFO & Executive VP of Finance	less than a year	US$3.32m	0.0023% $ 4.4m
Hubert Allen	Executive VP	11.7yrs	US$7.42m	0.011% $ 20.8m
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10yrs	US$5.93m	0.0072% $ 14.1m
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.7yrs	US$5.50m	0.0035% $ 6.9m
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	pas de données	pas de données
Michael Comilla	Vice President of Investor Relations.	no data	pas de données	pas de données
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	pas de données	pas de données
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	pas de données	pas de données
Christopher Scoggins	Senior Vice President of Commercial Operations	1.7yrs	pas de données	pas de données
Mary Moreland	Executive Vice President of Human Resources	5.1yrs	pas de données	0.0059% $ 11.5m
Jared Watkin	Executive Vice President of Diabetes Care	9.3yrs	pas de données	0.0041% $ 8.1m

5.7yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ABT est chevronnée et expérimentée (ancienneté moyenne 5.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Ford	Chairman of the Board	4.8yrs	US$23.27m	0.024% $ 46.9m
Daniel Starks	Independent Director	7.6yrs	US$349.29k	0.39% $ 754.4m
John Stratton	Independent Director	7.7yrs	US$341.96k	0.00020% $ 391.2k
Nancy McKinstry	Lead Independent Director	12.8yrs	US$405.96k	0.00027% $ 528.2k
Michael Roman	Independent Director	3.4yrs	US$337.96k	0% $ 0
Robert Alpern	Independent Director	15.9yrs	US$441.44k	0% $ 0
Michael O'Grady	Independent Director	1.4yrs	US$283.96k	0% $ 0
Michelle Kumbier	Independent Director	6.3yrs	US$331.96k	0.00018% $ 352.1k
Sally Blount	Independent Director	12.8yrs	US$362.60k	0.00015% $ 293.4k
Claire Babineaux-Fontenot	Independent Director	2yrs	US$354.96k	0% $ 0
Darren McDew	Independent Director	5yrs	US$331.19k	0% $ 0
Patricia Gonzalez	Independent Director	3.1yrs	US$356.96k	0% $ 0

5.6yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ABT sont considérés comme expérimentés (ancienneté moyenne 5.5 ans).

Abbott Laboratories Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Chairman of the Board notifies of intention to sell stock

Executive Vice President of Finance notifies of intention to sell stock

Insider recently sold US$2.4m worth of stock

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Insider exercised options and sold US$2.6m worth of stock

Insider notifies of intention to sell stock

Recent updates

Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Chairman of the Board notifies of intention to sell stock

Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Driving Value By Scaling Innovations

Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors

Second quarter 2024 earnings: EPS misses analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

First quarter dividend of US$0.55 announced

Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)

Abbott Laboratories: Why I Agree With Wall Street On This One

Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock

Executive Vice President of Finance notifies of intention to sell stock

New minor risk - Insider selling

Insider recently sold US$2.4m worth of stock

First quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Fourth quarter dividend of US$0.55 announced

Now 20% overvalued after recent price rise

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Insider exercised options and sold US$2.6m worth of stock

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Insider notifies of intention to sell stock

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration